Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

An Iridociliochoroidal Myeloid Sarcoma Associated With Relapsed Acute Myeloid Leukemia With FLT3-ITD Mutation, Treated With Gilteritinib, an FLT3 Inhibitor

An Iridociliochoroidal Myeloid Sarcoma Associated With Relapsed Acute Myeloid Leukemia With... This case report presents the response to experimental drug gilteritinib hemifumarate in a patient with ophthalmological complications of relapsed acute myeloid leukemia with FMS-like tyrosine kinase 3 (FLT3) gene mutation. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

An Iridociliochoroidal Myeloid Sarcoma Associated With Relapsed Acute Myeloid Leukemia With FLT3-ITD Mutation, Treated With Gilteritinib, an FLT3 Inhibitor

Loading next page...
 
/lp/american-medical-association/an-iridociliochoroidal-myeloid-sarcoma-associated-with-relapsed-acute-UsLH4jS2eh
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/jamaophthalmol.2020.0110
Publisher site
See Article on Publisher Site

Abstract

This case report presents the response to experimental drug gilteritinib hemifumarate in a patient with ophthalmological complications of relapsed acute myeloid leukemia with FMS-like tyrosine kinase 3 (FLT3) gene mutation.

Journal

JAMA OphthalmologyAmerican Medical Association

Published: Apr 12, 2020

References